Abstract:Objective To study the changes in T cell subsets and IL-7 in HIV-1-infected patients after seven years of highly active antiretroviral therapy (HAART). Methods Seventy-five individuals were included in this study (25 with effective HAART, 18 with ineffective HAART, 17 untreated HIV+ patients, and 15 volunteers in the HIV negative control group). The counts of CD4 + , CD8 + , CD8/CD38 + , and CD8/HLADR + T cells as well as the IL-7 protein expression was measured at 5 time points during a period of seven years in patients starting HAART (baseline) and in the HIV negative control group. The expression of CD127 on CD3 + T cells was measured by flow cytometry at a single time point (after 7 years) in patients with HAART and was compared with untreated HIV+ patients and the HIV negative control group. Results At baseline CD4 + T cell counts of HIV-1-infected patients were lower than that in the control group (p < 0.01), whereas the CD8 + , CD8/HLADR + and CD8/CD38 + T cell counts were higher than those in the control group ( p < 0.01). After seven years of effective HAART, the CD4 + T cell counts had increased and the CD8 + T cell count had decreased, although not to the normal levels ( p < 0.05). Both the CD8/HLADR + and CD8/CD38 + T cell counts had gradually approached those of the control group ( p > 0.05). In the ineffective HAART group, the CD8/CD38 + T cell count had not decreased significantly, and CD8/HLADR + T cell count gradually decreased. Before treatment, IL-7 serum levels of patients were significantly higher than that in the control group ( p < 0.01). After seven years of effective HAART, IL-7 levels had gradually decreased, but were still higher than in the control group ( p < 0.01). The CD127 expression on CD3 + CD8 + T cells in effective HAART patients was higher than in untreated HIV+ patients ( p < 0.05), but was lower than that in the control group ( p < 0.05). CD127 expression on CD3 + CD4+ T cells was not significantly different among the control group, untreated HIV+ patients and effective HAART group. Conclusion After seven years of effective HAART, the quantity and capacity of T cell subsets and IL-7 in HIV-1-infected patients had been partially restored, and the abnormal immune activation has significantly diminished.

Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated During Acute HIV-1 Infection.

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

[Impact of Long-Term Highly Active Antiretroviral Therapy on Bone Metabolism in AIDS Patients].

Study of T Cell subsets and IL-7 protein expression in HIV-1-infected patients after 7 years HAART

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial

Impact of Highly Active Antiretroviral Treatment on Expression of HIV-1 Coreceptors and Ligand Levels in Peripheral Blood from HIV-1 Infected Patients in China

Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

Effect of Long-Term Highly Active Antiretroviral Therapy on Abnormal Immune Activation and Immune Reconstruction in HIV-1 Infected Individuals

Immune reconstitution in HIV-1 infected individuals with long-term highly active antiretroviral therapy

[Clinical Impacts of Highly Active Antiretroviral Therapy on Patients of Hemophilia Combined with Acquired Immunodeficiency Syndrome: 6-Year Follow-Up of 39 Cases].

[Impact of Highly Active Antiretroviral Therapy on Plasma MCP-1 and MSP in AIDS Patients].

Evalution of highly active antiretroviral therapy in 182 patients with HIV/AIDS

Effective Treatment of Patients Experiencing Primary, Acute HIV Infection Decreases Exhausted/Activated CD4+ T Cells and CD8+ T Memory Stem Cells

Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy

The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine